- Report
- December 2024
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- July 2024
- 144 Pages
Global
From €2842EUR$2,990USD£2,388GBP
- Report
- December 2024
- 120 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- December 2024
- 150 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- July 2019
- 266 Pages
Global
From €3327EUR$3,500USD£2,795GBP
- Report
- May 2019
- 73 Pages
Global
From €808EUR$850USD£679GBP
- Report
- October 2023
- 175 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2021
- 140 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- October 2024
- 86 Pages
Global
From €3500EUR$3,944USD£3,043GBP
Bioresorbable coronary stents are a type of cardiovascular device used to treat coronary artery disease. They are designed to be implanted in the coronary artery to open a blocked artery and restore blood flow. Unlike traditional metal stents, bioresorbable stents are made of biodegradable polymers that dissolve over time, allowing the artery to return to its natural state. This technology has the potential to reduce the risk of long-term complications associated with metal stents, such as restenosis and late stent thrombosis.
Bioresorbable coronary stents are still in the early stages of development, but the market is expected to grow rapidly in the coming years. Companies are investing heavily in research and development to improve the safety and efficacy of these devices.
Some of the major players in the bioresorbable coronary stents market include Abbott, Biotronik, Boston Scientific, Elixir Medical, and Medtronic. Show Less Read more